阿德福韦酯初治老年慢性乙型肝炎患者3年临床疗效和安全性观察

doi:10.3969/.j.issn.1672-5069.2015.06.007

摘要/Abstract

摘要： 目的观察阿德福韦酯初治老年慢性乙型肝炎患者的抗病毒疗效和安全性。方法选取2007年10 月至2010年10 月就诊的50例65 岁以上老年慢性乙型肝炎患者,其中30例（A组）接受阿德福韦酯抗病毒治疗,另20例（B组）接受护肝治疗;另选择30例（C组）中年患者接受阿德福韦酯治疗。结果在治疗12 w时, A组（66.7%）和B组（60.0%）血清ALT复常率明显低于C组（83.3%,P<0.05）;在治疗48 w时,A组（90.0%）与C组（93.3%）比,ALT复常率无显著性差异（P>0.05）,但均高于B组（70.0%,P<0.05）;在48 w时,A组血清HBV DNA阴转率（80.0%）明显高于C组（66.7%,P<0.05）;3组患者在随访期间血肌酐水平变化的差异无统计学意义（P>0.05;3组患者在各时间点的平均肌酐水平差异无统计学意义,但在治疗96 w时,A组2例出现肌酐轻度升高,继续观察2个月后自行恢复正常,C组出现肌酐轻度升高3例,3个月内未恢复, 给予ADV剂量减半后血肌酐均恢复正常,两组抗病毒治疗的患者均未见其它明显的不良反应。结论老年慢性乙型肝炎患者可选择阿德福韦酯抗病毒治疗,其疗效好,安全,与中年患者相比,无明显的肾功能损害。

关键词: 慢性乙型肝炎, 阿德福韦酯, 疗效, 肾功能, 老年

Abstract: ObjectiveTo observe the antiviral efficacy and safety of adefovir in the treatment of elderly patients with hepatitis B. MethodsFifty elderly patients aged over 65 year old with chronic hepatitis B （CHB） were divided into group A（n=30）and group B（n=20）,and thirty patients with hepatitis B aged （46.31±2.18） yr were selected in group C who took adefovir at dose of 10 mg daily as initial treatment as the same treatment as in group A. The three groups were observed at admission,12 weeks,24 weeks,48 weeks,96 weeks and 144 weeks after treatment for virologic response and renal functions. All patients were followed-up for three years. Results At 24 weeks,there was no significant difference of liver normalization rates in group A （83.6%） and group C（86.7%）;At 48 weeks and 96 weeks,serum HBV DNA loss rate in group A was obviously higher than that in group C（80.0% and 80.0% vs. 60.0% and 66.7%,respectively,P<0.05）;At the end of three years,there was no statistically significant difference of blood creatinine in the three groups;At 96 week treatment,2 patients in group A had blood creatinine levels mildly elevated,but returning to normal after 2 month observation,3 cases in group C had mild abnormal creatinine elevation,not recovered within three months,but got back to normal when the dosage of adefovir half-decreased. Conclusion The application of adefovir in elderly patients with chronic hepatitis B can improve liver functions,and have a good antiviral efficacy.

Key words: Hepatitis B, Adefovir, Efficacy, Renal functions, Elderly

胡侠，王开鉴，周岳进，胡操寒，卢成鸿，郑金莉，潘华将. 阿德福韦酯初治老年慢性乙型肝炎患者3年临床疗效和安全性观察[J]. 实用肝脏病杂志, 2015, 18(6): 590-593.

Hu Xia， Wang Kaijian， Zhou Yuejin， et al.. Observation of adefovir dipivoxil in treatment of elderly patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 590-593.

参考文献

[1] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南.实用肝脏病杂志,2006,9：8-18.
[2] 王一歌,邹士辉. 阿德福韦酯治疗慢性乙型肝炎临床疗效及影响因素的研究. 中国实用医药,2011,17（6）39-41.
[3] 骆抗先,陈金军,李平,等. 乙型肝炎基础和临床.1版,北京.人民卫生出版社,2012:498-508.
[4] 宋国凤,陈志伟,高明宏.老年性病毒性肝炎的特点.中国当代医药,2009,16（12）:158-162.
[5] 慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识.中华实验和临床感染病杂志.电子版,2010,4（2）,192-199.
[6] Tsang PS,Trinh H,Garcia RT,et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly serum alanine aminptransferase levels.Clin Gastroenterol Hepatol,2008,6:569-574.
[7] Dusheiko G. Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B：a review of the major clinical studies. J Hepatol,2003,39（Suppl1）: S116-S123.
[8] Tillmann HL. Antiviral therapy and resistancewith hepatitis B virus infection.World J Gastroenterol,2007,13（1）： 125-140.
[9] Reijnders JG,LeemansWF,Hansen BE,et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B:virologic response can be assessed at 24 weeks. J Viral Hepat,2009,16（2）：113-120.
[10] 李向永,林国莉,吴云凯,等.慢性乙型肝炎阿德福韦酯疗效欠佳影响因素分析及优化治疗疗效的探讨.中华实验和临床感染病杂志,电子版,2011,5（2）：155-161.
[11] Buti M,Elefsiniotis I,Jardi R,et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol,2007,47（3）:366-372.
[12] 谢欣城,张永乐,张思泉,等. 阿德福韦酯治疗慢性乙型肝炎产生耐药变异与病毒载量的关系.中华医院感染学杂志,2011,21（8）：1517-1519.
[13] 尚莉莉.阿德福韦酯治疗慢性乙型肝炎疗效观察.蚌埠医学院学报,2010,35（1）：54-55.
[14] 张文君.阿德福韦酯治疗低病毒载量乙型肝炎相关活动性肝硬化的疗效.胃肠病学和肝病学杂志,2013,22（5）：459-460.
[15] 朱银芳,严志涵,俞萍,等.阿德福韦酯治疗低复制慢性乙型肝炎3年疗效评估.肝脏,2014,19（1）：80-81.
[16] 吉英杰,张文瑾,范振平,等.阿德福韦酯治疗老年慢性乙肝患者的安全性及疗效.中华老年多器官疾病杂志,2010,9（6）：501-504.
[17] Hoeslin DC,Mendel DB. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter. J Am Soc Nephrol,2000,11（ 3）：383-393.
[18] ADHOC International Steering Committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection:the ADHOC trial. HIV Med,2002,3（2）：229-238.
[19] 王桂爽,蔡洁东. 阿德福韦酯和替诺福韦酯相关肾小管病.药物不良反应杂志,2012,12（1）：31-36.
[20] Hassane I,Jean SH,Vincent LV,et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind,randomized,placebo-controlled studies. Kid Int,2004,66（8）： 1153-1158.
[21] Hanzitannis SJ,Tassopoulos NC,Heathcote EJ,et al. Adefovir Dipivoxil 438 Study Group,long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131（12）：1743-1751.
[22] Patrick M,Ting-Tsung C,Seng G,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med,2003,348 （6）:808- 816.
[23] Noble S,Goak L.Adefovir dipivoxil. Drugs,1999,58（4）：479-487.